These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22202059)

  • 41. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
    Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
    Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. βig-h3 supports gastric cancer cell adhesion, migration and proliferation in peritoneal carcinomatosis.
    Li Z; Miao Z; Jin G; Li X; Li H; Lv Z; Xu HM
    Mol Med Rep; 2012 Sep; 6(3):558-64. PubMed ID: 22710407
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selection criteria for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer.
    Königsrainer I
    World J Gastroenterol; 2011 Oct; 17(37):4153-6. PubMed ID: 22072845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
    Scala S
    Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
    Mitchell B; Mahalingam M
    Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Positive Cross-Talk Between CXC Chemokine Receptor 4 (CXCR4) and Epidermal Growth Factor Receptor (EGFR) Promotes Gastric Cancer Metastasis via the Nuclear Factor kappa B (NF-kB)-Dependent Pathway.
    Cheng Y; Che X; Zhang S; Guo T; He X; Liu Y; Qu X
    Med Sci Monit; 2020 Sep; 26():e925019. PubMed ID: 32881844
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
    Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
    Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
    Terasaki M; Sugita Y; Arakawa F; Okada Y; Ohshima K; Shigemori M
    Brain Tumor Pathol; 2011 Apr; 28(2):89-97. PubMed ID: 21210239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
    Liepelt A; Tacke F
    Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hypoxia induces CXCR4 expression and biological activity in gastric cancer cells through activation of hypoxia-inducible factor-1α.
    Oh YS; Kim HY; Song IC; Yun HJ; Jo DY; Kim S; Lee HJ
    Oncol Rep; 2012 Dec; 28(6):2239-46. PubMed ID: 23023480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Chemokine receptor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12.
    Singh AK; Arya RK; Trivedi AK; Sanyal S; Baral R; Dormond O; Briscoe DM; Datta D
    Cytokine Growth Factor Rev; 2013 Feb; 24(1):41-9. PubMed ID: 22989616
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CXC chemokine ligand 12 (CXCL12) and its receptor CXCR4.
    Nagasawa T
    J Mol Med (Berl); 2014 May; 92(5):433-9. PubMed ID: 24722947
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retinoblastoma tumor suppressor gene 1 enhances 5-Fluorouracil chemosensitivity through SDF-1/CXCR4 axis by regulating autophagy in gastric cancer.
    Tang H; Long Q; Zhuang K; Han K; Zhang X; Guo H; Lu X
    Pathol Res Pract; 2021 Aug; 224():153532. PubMed ID: 34214844
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
    Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
    Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential.
    Wald O; Shapira OM; Izhar U
    Theranostics; 2013; 3(1):26-33. PubMed ID: 23382783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
    Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Sidharta PN
    Pharmacol Res; 2020 Nov; 161():105092. PubMed ID: 32758634
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
    Mao TL; Fan KF; Liu CL
    Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The CXCL12-CXCR4 axis promotes migration, invasiveness, and EMT in human papillary thyroid carcinoma B-CPAP cells via NF-κB signaling.
    Lin Y; Ma Q; Li L; Wang H
    Biochem Cell Biol; 2018 Oct; 96(5):619-626. PubMed ID: 29316404
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: Implications for therapeutic interventions in cancer and immune-mediated diseases.
    Britton C; Poznansky MC; Reeves P
    FASEB J; 2021 Apr; 35(4):e21260. PubMed ID: 33715207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.